Partnership
Creating values and growth

Are you interested in being part of this unique venture? 

The Israel Innovation Authority (IIA) and various investors are! Liposphere is supported via the IIA’s Women’s Entrepreneur Track to accelerate the commercialization of our intra-articular injectable to treat Osteoarthritis. Moreover, we are very proud to have an outstanding network of investors behind us to join forces to accomplish our vision and to be able to explore Coat by Liposphere’s potential in the context of different markets.

The great strength of the technology based on its platform opportunities and innovative nature as such is highly valued among investors and hence de-risks investments.

Office:        +972 (0) 732113227
E-Mail:      

Investor account

Innovations heading for
market leadership

Efficient water-based biolubricants are of need in many technological and medical market segments. With the focus on the orthopaedic, ophthalmic and coating sector, we intend to penetrate highly mature, competitive, but growing markets.

The growth of the orthopaedic injectable market is driven by an increase in the geriatric population. And longer life spans and metabolic diseases impacting orthopaedic conditions.

Global annual market size by
2025

*Source: Lubricants Market Size, Share & Trends Anylysis Report By Product 2019-2025; Grand View Research

Our strategic business areas

Why Liposphere?
Performance coatings on biological and synthetic surfaces

Liposphere is a young, dynamic company with massive innovation potential originating from its IP-protected platform technology of unmatched water-based lubricants. In-vitro, on solid surfaces, Liposphere’s basic formulation outperforms hyaluronic acid-based solutions dramatically (by 2-3 orders of magnitude) in terms of lubrication capability (7) and wear reduction performance. In clinical trials conducted so far, CCoat has been shown to be safe to use and highly effective to improve functionality of the joint.

„We believe that Coat by Liposphere

has the potential to revolutionize the
market of
water-based lubricants.

Taken together, our deep scientific expertise and experience in product development in combination with a tremendously strong advisory and support from the Israel Innovation Authority give Liposphere a  unique position for the upcoming years!

News from Liposphere

28
May
Winner of ATiO’s „Best Early-Stage Company Award“!
Excitement about AqueousJoint’s development among a high-profile orthopedic community.

Liposphere presented its AqueousJoint knee joint injectable at the Alliance for Advanced Therapies in Orthopedics (ATiO, https://atioalliance.org/) conference in Berlin. Following competitive rounds of presentations, the Company won the Best Early-Stage Company award judged by a high-profile orthopedic audience and received the „Dancing Bear“ trophy.

04
Apr
Approval of multi-centered, double-blinded clinical trial
150 patients will be recruited at different clinical sites in Israel.

The Israeli Ministry of Health approved our efficacy-focused clinical trial protocol. The trial will be a multi-center, double-blinded, and randomized study, and the primary outcome is to show the superiority of the CCoat product compared to a saline solution (Placebo). Moreover, low, and high dosages of AqueousJoint will be used to identify the optimum product concentration.
Each group will recruit 50 patients to achieve statistically meaningful results.
The first clinical site in Assuta Hospital, Ashdod, was initiated. Further sites are Kaplan Hospital, Rehovot, Tel-Hashomer, Ramat-Gan, and Asaf Harofe Beer-Yacov, which will open soon to expedite recruitment.

02
Feb
First-In-Human clinical trial successfully completed
Promising clinical outcome!

20 Patients with diagnosed Osteoarthritis were enrolled in our First-In-Human safety trial in which the AqueousJoint product was clinically evaluated for the first time. Those patients received a single AqueousJoint injection into their knee joint cavity.
A follow-up time of 6 months was completed successfully, confirming the product’s safety (no related adverse events reported) and a long-lasting pain reduction effect of 6 months. The efficacy output was assessed using standardized questionnaires: The Knee Injury and Osteoarthritis Outcome Score (KOOS) and a Numeric Visual Scale (NVS) measure.

 

 

 

 

 

 

 

 

Social News
Follow us on LinkedIn
and stay connected

There is always exciting progress and news in our field of development and we are proud to be part of this dynamic process of shaping our future together. If you want to be part of this exciting journey and want to know today everything, that is new tomorrow, join us on LinkedIn!

 

     

Contact us

Would you like to contact us? Call us or send us a message using the contact form – looking forward to hear from you.

 

Liposphere Ltd.
PAarava 1
6th Floor
Givat-Shmuel 5400804
Israel

Office:  +972 (0) 732113227
E-Mail:  


    * Required